Predicting human drug pharmacokinetics from in vitro permeability using an absorption-disposition model

Journal of Pharmaceutical Sciences

Volumn 96, Issue 8, 2007, Pages 2161-2170

  Fliszar, Kyle A ^a   Hill, Brian T ^a   Foster, Natalie ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b LEHIGH UNIVERSITY   (United States)

Author keywords

Absorption; Dissolution; Permeability; Predictive model

Indexed keywords

ACICLOVIR; ALFENTANIL; ATENOLOL; DIDANOSINE; DILTIAZEM; ETORICOXIB; HYDROCHLOROTHIAZIDE; METFORMIN; METOPROLOL; NADOLOL; PINDOLOL; PROPRANOLOL DERIVATIVE; ROFECOXIB;

AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KINETICS;

EID: 34548105910     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20866     Document Type: Article

References (39)

1. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Delivery Rev 23:3-25.
2. Ho NFH, Park J, No P, Higuchi W. 1983. Advanced quantitative and mechanistic approaches in interfacing gastrointestinal drug absorption studies in animals and humans. Animal models for oral drug delivery in man: In situ and in vivo approaches. American Pharmaceutical Association, Washington, DC. pp 27-106.
3. Dressman JB, Fleisher D, Amidon GL. 1984. Physiochemical model for dose dependent drug absorption. J Pharm Sci 73:1274-1279.
4. Amidon GL, Lennernas H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413-420.
5. Takka S, Sakr A, Goldberg A. 2003. Development and validation of an in vitro-in vivo correlation for buspirone hydrochloride extended release tablets. J Cont Rel 88:147-157.
6. Corrigan OI, Devlin Y, Butler J. 2003. Influence of dissolution medium buffer composition on ketoprofen release from ER products and in vitro-in vivo correlation. Int J Pharm 254:147-154.
7. Sirisuth N, Augsburger L, Eddington N. 2002. Development and validation of a non-linear IVIVC model for a diltiazem extended release formulation. Biopharm Drug Disp 23:1-8.
8. Veng-Pedersen P, Gobburu JVS, Meyer MC, Straughn AB. 2000. Carbamazepine level-A in vivo-in vitro correlation (IVIVC): A scaled convolution based predictive approach. Biopharm Drug Disp 21:1-6.
9. Lake OA, Olling M, Barends DM. 1999. In vitro/in vivo correlations of dissolution data of carbamazepine immediate release tablets with pharmacokinetic data obtained in healthy volunteers. Eur J Pharm Biopharm 48:13-19.
10. Dutta S, Qiu Y, Samara E, Cao G, Granneman R. 2005. Once-A-Day extended-release dosage form of divalproex sodium III: Development and validation of a level A in vitro-in vivo correlation (IVIVC). J Pharm Sci 94:1949-1956.
11. Drewe J, Guitard P. 1993. In vitro-in vivo correlation for modified release dosage forms. J Pharm Sci 82:132-137.
12. Willmann S, Schmitt W, Keldenich J, Lipert J, Dressman J. 2003. A physiological model for the estimation of the fraction dose absorbed in humans. J Med Chem 47:4022-4031.
13. Wohnsland F, Faller B. 2000. High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes. J Med Chem 44:923-930.
14. Yu LX, Amidon GL. 1999. A compartmental absorption and transit model for estimating oral drug absorption. Int J Pharm 186:119-125.
15. Dressman JB, Fleisher D, Amidon GL. 1984. Physiochemical model for dose dependent drug absorption. J Pharm Sci 73:1274-1279.
16. Zhao YH, Le J, Abraham MH, Hersey A, Eddershaw PJ, Luscombe CN, Butina D, Beck G, Sherborne B, Cooper I, et al. 2001. Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the Abraham descriptors. J Pharm Sci 90:749-784.
17. a. J Pharm Exp Ther 314:391-399.
18. Tavelin S, Taipalensuu J, Soderberg L, Morrison R, Chong S, Artursson P. 2003. Prediction of the oral absorption of low-permeability drugs using small intestine-like 2/4/A1 cell monolayers. Pharm Res 20:397-404.
19. Chiou W. 2001. The rate and extent of oral bioavailability versus the rate and extent of oral absorption: Clarification and recommendation of terminology. J Pharmacokinet Pharmacodyn 28:3-6.
20. Davenport HW. 1982. Physiology of the digestive tract, 5th edition. Chicago, IL: Year Book Medical Publishers, Inc.
21. Rowland M, Tozer TN. 1995. Clinical pharmacokinetics: Concepts and applications, 3rd edition. Media, PA: Williams & Wilkins.
22. Poulin P, Schoenlein K, Theil FP. 2001. Prediction of adipose tissue: Plasma partition coefficients for structurally unrelated drugs. J Pharm Sci 90:436-447.
23. Snyder WS, Cook MJ, Nasset ES, Karhuasen LR, Howells GP, Tipton IH. 1975. Report of the task group on reference man, New York: Pergamon.
24. Yu LX, Gatlin L, Amidon GL. 2000. Predicting oral drug absorption in humans. In: Amidon GL, Lee PI, Topp EM, editors. Transport processes in pharmaceutical systems. New York: Marcel Dekker, Inc. pp 377-409.
25. Kimura T, Higaki K. 2002. Gastrointestinal transit and drug absorption. Biol Pharm Bull 25:149-164.
26. Gimenez F, Foeillet E, Bourdon O, Weller S, Garret C, Bidault R, Singlas E. 2004. Evaluation of pharmacokinetic interactions after oral administration of mycophenolate mofetil and valaciclovir or aciclovir to healthy subjects. Clin Pharm 43:685-692.
27. Mertens M, Vuyk J, Olofsen E, Bovill J, Burm A. 2001. Propofol alters the pharmacokinetics of alfentanil in healthy male volunteers. Anesthesiology 94:949-957.
28. Sabanathan K, Castleden C, Adam H, Ryan J, Fitzsimons T. 1987. A comparative study of the pharmacokinetics and pharamacodynamics of atenolol, hydrochlorothiazide and amiloride in normal young and elderly subjects and elderly hypertensive patients. Eur J Clin Pharm 32:53-60.
29. Hoetelmans R, Heeswijk R, Profijt M, Mulder J, Meenhorst P, Lange J, Reiss P, Beijnen J. 1998. Comparison of the plasma pharmacokinetics and renal clearance of didanosine during once and twice daily dosing in HIV-1 infected individuals. AIDS 12:F211-F216.
30. Weir S, Dimmitt D, Lanman R, Morrill M, Geising D. 1998. Steady-state pharmacokinetics of diltiaem and hydrochlorothiazide administered alone and in combination. Biopharm Drug Dispos 19:365-371.
31. Agrawal N, Porras A, Matthews C, Rose M, Woolf E, Musser B, Dynder A, Mazina K, Lasseter K, Hunt T, Schwartz J, McCrea J, Gottesdiener K. 2003. Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man. J Clin Pharm 43:268-276.
32. Luzier A, Killian A, Wilon J, Wilson M, Forrest A, Kazierad D. 1999. Gender-related effects on metoprolol pharmacokinetcis and pharmacodynamics in health volunteers. Clin Pharm Ther 66:594-601.
33. Srinivas N, Barr W, Shu W, Mohandoss E, Chow S, Staggers J, Balan G, Belas F, Blair I, Barbhaiya R. 1996. Bioequivalence of two tablet formulations of nadolol using single and multiple dose data: Assessment using sterospecific and nonstereospecific assays. J Pharm Sci 85:299-303.
34. Gugler R, Herold W, Dengler H. 1973. Pharmacokinetics of pindolol in man. Eur J Clin Pharm 7:17-24.
35. Wojcicki J, Sulzyc-Bielicka V, Kutrzeba J, Gawronska-Szklarz B, Drozdzik M, Sterna Z. 1999. Studies on the pharmacokinetics and pharmacodynamics of propranolol in hyperlipdemia. J Clin Pharm 39:826-833.
36. Buvanendran A, Kroin J, Tuman K, Lubenow T, Elmofty D, Luk P. 2005. Cerebrospinal fluid and plasma pharmacokinetics of the cyclooxygenase 2 inhibitor rofecoxib in humans: Single and multiple oral drug administration. Anesth Analg 100:1320-1324.
37. Terao T, Hisanaga E, Sai Y, Tamai I, Tsuji A. 1996. Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J Pharm Pharmacol 48:1083-1089.
38. Mahony W, Domin B, McConnel R, Zimmerman T. 1988. Acyclovir transport in human erythrocytes. J Biol Chem 263:9285-9291.
39. Matsson P, Bergstrom C, Nagahara N, Tavelin S, Norinder U, Artursson P. 2005. Exploring the role of different drug transport routes in permeability screening. J Med Chem 48:604-613.